Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 968

1.

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study.

Legdeur N, Badissi M, Carter SF, de Crom S, van de Kreeke A, Vreeswijk R, Trappenburg MC, Oudega ML, Koek HL, van Campen JP, Keijsers CJPW, Amadi C, Hinz R, Gordon MF, Novak G, Podhorna J, Serné E, Verbraak F, Yaqub M, Hillebrand A, Griffa A, Pendleton N, Kramer SE, Teunissen CE, Lammertsma A, Barkhof F, van Berckel BNM, Scheltens P, Muller M, Maier AB, Herholz K, Visser PJ.

BMC Geriatr. 2018 Nov 26;18(1):289. doi: 10.1186/s12877-018-0984-z.

2.

In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET.

Hagens MHJ, Golla SV, Wijburg MT, Yaqub M, Heijtel D, Steenwijk MD, Schober P, Brevé JJP, Schuit RC, Reekie TA, Kassiou M, van Dam AM, Windhorst AD, Killestein J, Barkhof F, van Berckel BNM, Lammertsma AA.

J Neuroinflammation. 2018 Nov 13;15(1):314. doi: 10.1186/s12974-018-1352-9.

3.

Preoperative Resectability Estimates of Nonenhancing Glioma by Neurosurgeons and a Resection Probability Map.

Hendriks EJ, Idema S, Hervey-Jumper SL, Bernat AL, Zwinderman AH, Barkhof F, Vandertop WP, Mandonnet E, Duffau H, Berger MS, De Witt Hamer PC.

Neurosurgery. 2018 Nov 10. doi: 10.1093/neuros/nyy487. [Epub ahead of print]

PMID:
30423155
4.

Secondary prevention of Alzheimer's dementia: neuroimaging contributions.

Ten Kate M, Ingala S, Schwarz AJ, Fox NC, Chételat G, van Berckel BNM, Ewers M, Foley C, Gispert JD, Hill D, Irizarry MC, Lammertsma AA, Molinuevo JL, Ritchie C, Scheltens P, Schmidt ME, Visser PJ, Waldman A, Wardlaw J, Haller S, Barkhof F.

Alzheimers Res Ther. 2018 Oct 30;10(1):112. doi: 10.1186/s13195-018-0438-z.

5.

Cardiovascular Risk Factors and White Matter Hyperintensities: Difference in Susceptibility in South Asians Compared With Europeans.

Sudre CH, Smith L, Atkinson D, Chaturvedi N, Ourselin S, Barkhof F, Hughes AD, Jäger HR, Cardoso MJ.

J Am Heart Assoc. 2018 Nov 6;7(21):e010533. doi: 10.1161/JAHA.118.010533.

6.

Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline.

Ten Kate M, Dicks E, Visser PJ, van der Flier WM, Teunissen CE, Barkhof F, Scheltens P, Tijms BM; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2018 Dec 1;141(12):3443-3456. doi: 10.1093/brain/awy264.

PMID:
30351346
7.

Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease.

Groot C, Sudre CH, Barkhof F, Teunissen CE, van Berckel BNM, Seo SW, Ourselin S, Scheltens P, Cardoso MJ, van der Flier WM, Ossenkoppele R.

Neurology. 2018 Nov 13;91(20):e1851-e1859. doi: 10.1212/WNL.0000000000006503. Epub 2018 Oct 19.

PMID:
30341156
8.

AMYPAD Diagnostic and Patient Management Study: Rationale and design.

Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Alves IL, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott J, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N.

Alzheimers Dement. 2018 Oct 16. pii: S1552-5260(18)33528-3. doi: 10.1016/j.jalz.2018.09.003. [Epub ahead of print]

9.

Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions.

van de Kreeke JA, Nguyen HT, Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Sudre CH, Barkhof F, Boomsma DI, Tan HS, Verbraak FD, Visser PJ.

Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5025-5031. doi: 10.1167/iovs.18-25341.

PMID:
30326071
10.

Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies.

Hu X, Teunissen CE, Spottke A, Heneka MT, Düzel E, Peters O, Li S, Priller J, Buerger K, Teipel S, Laske C, Verfaillie SCJ, Barkhof F, Coll-Padrós N, Rami L, Molinuevo JL, van der Flier WM, Jessen F.

Alzheimers Dement. 2018 Oct 12. pii: S1552-5260(18)33527-1. doi: 10.1016/j.jalz.2018.09.002. [Epub ahead of print]

PMID:
30321506
11.

Evaluating combinations of diagnostic tests to discriminate different dementia types.

Bruun M, Rhodius-Meester HFM, Koikkalainen J, Baroni M, Gjerum L, Lemstra AW, Barkhof F, Remes AM, Urhemaa T, Tolonen A, Rueckert D, van Gils M, Frederiksen KS, Waldemar G, Scheltens P, Mecocci P, Soininen H, Lötjönen J, Hasselbalch SG, van der Flier WM.

Alzheimers Dement (Amst). 2018 Aug 17;10:509-518. doi: 10.1016/j.dadm.2018.07.003. eCollection 2018.

12.

Assessing Amyloid Pathology in Cognitively Normal Subjects using [18F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods.

Collij L, Konijnenberg E, Reimand J, Ten Kate M, Den Braber A, Lopes Alves I, Zwan M, Yaqub M, Van Assema D, Wink AM, Lammertsma A, Scheltens P, Visser PJ, Barkhof F, Van Berckel B.

J Nucl Med. 2018 Oct 12. pii: jnumed.118.211532. doi: 10.2967/jnumed.118.211532. [Epub ahead of print]

PMID:
30315145
13.

Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study.

Leeuwis AE, Smith LA, Melbourne A, Hughes AD, Richards M, Prins ND, Sokolska M, Atkinson D, Tillin T, Jäger HR, Chaturvedi N, van der Flier WM, Barkhof F.

Front Aging Neurosci. 2018 Sep 18;10:279. doi: 10.3389/fnagi.2018.00279. eCollection 2018.

14.

The hippocampus in multiple sclerosis.

Rocca MA, Barkhof F, De Luca J, Frisén J, Geurts JJG, Hulst HE, Sastre-Garriga J, Filippi M; MAGNIMS Study Group.

Lancet Neurol. 2018 Oct;17(10):918-926. doi: 10.1016/S1474-4422(18)30309-0. Epub 2018 Sep 18. Review.

PMID:
30264730
15.

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.

Ten Kate M, Redolfi A, Peira E, Bos I, Vos SJ, Vandenberghe R, Gabel S, Schaeverbeke J, Scheltens P, Blin O, Richardson JC, Bordet R, Wallin A, Eckerstrom C, Molinuevo JL, Engelborghs S, Van Broeckhoven C, Martinez-Lage P, Popp J, Tsolaki M, Verhey FRJ, Baird AL, Legido-Quigley C, Bertram L, Dobricic V, Zetterberg H, Lovestone S, Streffer J, Bianchetti S, Novak GP, Revillard J, Gordon MF, Xie Z, Wottschel V, Frisoni G, Visser PJ, Barkhof F.

Alzheimers Res Ther. 2018 Sep 27;10(1):100. doi: 10.1186/s13195-018-0428-1.

16.

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.

Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators.

Alzheimers Res Ther. 2018 Sep 27;10(1):99. doi: 10.1186/s13195-018-0409-4.

17.

Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.

Eijlers AJC, van Geest Q, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, Barkhof F, Uitdehaag BMJ, Schoonheim MM, Geurts JJG.

Brain. 2018 Sep 1;141(9):2605-2618. doi: 10.1093/brain/awy202.

PMID:
30169585
18.

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network.

BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944.

19.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2018 Aug 28. doi: 10.1007/s11682-018-9942-9. [Epub ahead of print]

PMID:
30155789
20.

Functional brain network centrality is related to APOE genotype in cognitively normal elderly.

Wink AM, Tijms BM, Ten Kate M, Raspor E, de Munck JC, Altena E, Ecay-Torres M, Clerigue M, Estanga A, Garcia-Sebastian M, Izagirre A, Martinez-Lage Alvarez P, Villanua J, Barkhof F, Sanz-Arigita E.

Brain Behav. 2018 Sep;8(9):e01080. doi: 10.1002/brb3.1080. Epub 2018 Aug 22.

21.

Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis.

Brownlee WJ, Miszkiel KA, Tur C, Barkhof F, Miller DH, Ciccarelli O.

Neurology. 2018 Sep 18;91(12):e1130-e1134. doi: 10.1212/WNL.0000000000006207. Epub 2018 Aug 17.

PMID:
30120132
22.

A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus.

Wolters EE, Golla SSV, Timmers T, Ossenkoppele R, van der Weijden CWJ, Scheltens P, Schwarte L, Schuit RC, Windhorst AD, Barkhof F, Yaqub M, Lammertsma AA, Boellaard R, van Berckel BNM.

EJNMMI Res. 2018 Aug 15;8(1):79. doi: 10.1186/s13550-018-0432-2.

23.

Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change.

Reus LM, Vijverberg EG, Tijms BM, Kate MT, Gossink F, Krudop WA, Campo MD, Teunissen CE, Barkhof F, van der Flier WM, Visser PJ, Dols A, Pijnenburg YA.

J Psychiatr Res. 2018 Sep;104:183-191. doi: 10.1016/j.jpsychires.2018.07.014. Epub 2018 Aug 1.

PMID:
30103065
24.

Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.

Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2018 Aug 12. pii: jnnp-2018-318261. doi: 10.1136/jnnp-2018-318261. [Epub ahead of print]

PMID:
30100552
25.

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results.

Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, Dols A, Bouwman FH, Prins ND, Barkhof F, Lammertsma AA, Van Berckel BNM, Scheltens P, Sikkes SAM, Van der Flier WM.

Alzheimers Res Ther. 2018 Aug 7;10(1):76. doi: 10.1186/s13195-018-0390-y.

26.

The EMIF-AD PreclinAD study: study design and baseline cohort overview.

Konijnenberg E, Carter SF, Ten Kate M, den Braber A, Tomassen J, Amadi C, Wesselman L, Nguyen HT, van de Kreeke JA, Yaqub M, Demuru M, Mulder SD, Hillebrand A, Bouwman FH, Teunissen CE, Serné EH, Moll AC, Verbraak FD, Hinz R, Pendleton N, Lammertsma AA, van Berckel BNM, Barkhof F, Boomsma DI, Scheltens P, Herholz K, Visser PJ.

Alzheimers Res Ther. 2018 Aug 4;10(1):75. doi: 10.1186/s13195-018-0406-7.

27.

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

de Wilde A, van Buchem MM, Otten RHJ, Bouwman F, Stephens A, Barkhof F, Scheltens P, van der Flier WM.

Alzheimers Res Ther. 2018 Jul 28;10(1):72. doi: 10.1186/s13195-018-0398-3. Review.

28.

Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma.

Groot C, Tolboom N, Ikonomovic MD, Lammertsma AA, Boon BDC, Barkhof F, Scheltens P, Klunk WE, Rozemuller AJM, Ossenkoppele R, van Berckel BNM.

J Alzheimers Dis. 2018;65(1):71-77. doi: 10.3233/JAD-180316.

PMID:
30040724
29.

Progressive brain rich-club network disruption from clinically isolated syndrome towards multiple sclerosis.

Shu N, Duan Y, Huang J, Ren Z, Liu Z, Dong H, Barkhof F, Li K, Liu Y.

Neuroimage Clin. 2018 Mar 28;19:232-239. doi: 10.1016/j.nicl.2018.03.034. eCollection 2018.

30.

Mapping Deep Gray Matter Iron in Multiple Sclerosis by Using Quantitative Magnetic Susceptibility.

Barkhof F, Thomas DL.

Radiology. 2018 Nov;289(2):497-498. doi: 10.1148/radiol.2018181274. Epub 2018 Jul 17. No abstract available.

PMID:
30015585
31.

Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease.

Scheltens NME, van der Weijden K, Adriaanse SM, van Assema D, Oomen PP, Krudop WA, Lammertsma AA, Barkhof F, Koene T, Teunissen CE, Scheltens P, van der Flier WM, Pijnenburg YAL, Yaqub M, Ossenkoppele R, van Berckel BNM.

Neuroimage Clin. 2018 May 22;19:625-632. doi: 10.1016/j.nicl.2018.05.024. eCollection 2018.

32.

Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI.

Amiri H, de Sitter A, Bendfeldt K, Battaglini M, Gandini Wheeler-Kingshott CAM, Calabrese M, Geurts JJG, Rocca MA, Sastre-Garriga J, Enzinger C, de Stefano N, Filippi M, Rovira Á, Barkhof F, Vrenken H; MAGNIMS Study Group.

Neuroimage Clin. 2018 Apr 26;19:466-475. doi: 10.1016/j.nicl.2018.04.023. eCollection 2018. Review.

33.

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.

Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, Molinuevo JL, Wallin A, Lleó A, Popp J, Martinez-Lage P, Baird A, Dobson R, Legido-Quigley C, Sleegers K, Van Broeckhoven C, Bertram L, Ten Kate M, Barkhof F, Zetterberg H, Lovestone S, Streffer J, Visser PJ.

Alzheimers Res Ther. 2018 Jul 6;10(1):64. doi: 10.1186/s13195-018-0396-5.

34.

Spinal cord atrophy rates: Ready for prime time in multiple sclerosis clinical trials?

Prados F, Barkhof F.

Neurology. 2018 Jul 24;91(4):157-158. doi: 10.1212/WNL.0000000000005873. Epub 2018 Jun 27. No abstract available.

PMID:
29950433
35.

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.

Hagens MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Ciccarelli O, Gasperini C, Lukas C, Wattjes MP, Barkhof F; MAGNIMS Study Group.

Neurology. 2018 Jul 17;91(3):e249-e257. doi: 10.1212/WNL.0000000000005825. Epub 2018 Jun 20.

36.

Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier.

Tolonen A, Rhodius-Meester HFM, Bruun M, Koikkalainen J, Barkhof F, Lemstra AW, Koene T, Scheltens P, Teunissen CE, Tong T, Guerrero R, Schuh A, Ledig C, Baroni M, Rueckert D, Soininen H, Remes AM, Waldemar G, Hasselbalch SG, Mecocci P, van der Flier WM, Lötjönen J.

Front Aging Neurosci. 2018 Apr 25;10:111. doi: 10.3389/fnagi.2018.00111. eCollection 2018.

37.

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.

de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, van Buchem MM, Zwan M, Ossenkoppele R, Yaqub M, Kunneman M, Smets EMA, Barkhof F, Lammertsma AA, Stephens A, van Lier E, Biessels GJ, van Berckel BN, Scheltens P.

JAMA Neurol. 2018 Sep 1;75(9):1062-1070. doi: 10.1001/jamaneurol.2018.1346.

PMID:
29889941
38.

Microbleeds are associated with depressive symptoms in Alzheimer's disease.

Leeuwis AE, Prins ND, Hooghiemstra AM, Benedictus MR, Scheltens P, Barkhof F, van der Flier WM.

Alzheimers Dement (Amst). 2017 Dec 6;10:112-120. doi: 10.1016/j.dadm.2017.11.006. eCollection 2018.

39.

Earliest radiological progression in glioblastoma by multidisciplinary consensus review.

Eijgelaar RS, Bruynzeel AME, Lagerwaard FJ, Müller DMJ, Teunissen FR, Barkhof F, van Herk M, De Witt Hamer PC, Witte MG.

J Neurooncol. 2018 Sep;139(3):591-598. doi: 10.1007/s11060-018-2896-3. Epub 2018 May 18.

40.

Progression of regional grey matter atrophy in multiple sclerosis.

Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O.

Brain. 2018 Jun 1;141(6):1665-1677. doi: 10.1093/brain/awy088.

41.

Peri-hippocampal developmental venous anomalies and memory loss: more than a normal variant?

Haller S, Barkhof F.

Neuroradiology. 2018 Jun;60(6):579-582. doi: 10.1007/s00234-018-2026-0. Epub 2018 Apr 26. No abstract available.

PMID:
29700565
42.

Disrupted Module Efficiency of Structural and Functional Brain Connectomes in Clinically Isolated Syndrome and Multiple Sclerosis.

Liu Y, Duan Y, Dong H, Barkhof F, Li K, Shu N.

Front Hum Neurosci. 2018 Apr 10;12:138. doi: 10.3389/fnhum.2018.00138. eCollection 2018.

43.

Accelerated executive functions decline and gray matter structural changes in middle-aged type 1 diabetes mellitus patients with proliferative retinopathy.

van Duinkerken E, Steenwijk MD, Klein M, Barkhof F, Mograbi DC, Diamant M, Snoek FJ, Ijzerman RG.

J Diabetes. 2018 Nov;10(11):835-846. doi: 10.1111/1753-0407.12773. Epub 2018 May 30.

PMID:
29665283
44.

Cortical and subcortical gray matter structural alterations in normoglycemic obese and type 2 diabetes patients: relationship with adiposity, glucose, and insulin.

Bernardes G, IJzerman RG, Ten Kulve JS, Barkhof F, Diamant M, Veltman DJ, Landeira-Fernandez J, van Bloemendaal L, van Duinkerken E.

Metab Brain Dis. 2018 Aug;33(4):1211-1222. doi: 10.1007/s11011-018-0223-5. Epub 2018 Apr 13.

45.

Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging.

Bouts MJRJ, Möller C, Hafkemeijer A, van Swieten JC, Dopper E, van der Flier WM, Vrenken H, Wink AM, Pijnenburg YAL, Scheltens P, Barkhof F, Schouten TM, de Vos F, Feis RA, van der Grond J, de Rooij M, Rombouts SARB.

J Alzheimers Dis. 2018;62(4):1827-1839. doi: 10.3233/JAD-170893.

PMID:
29614652
46.

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline.

Verfaillie SCJ, Slot RER, Dicks E, Prins ND, Overbeek JM, Teunissen CE, Scheltens P, Barkhof F, van der Flier WM, Tijms BM.

Hum Brain Mapp. 2018 Aug;39(8):3143-3151. doi: 10.1002/hbm.24065. Epub 2018 Mar 30.

47.

Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults.

Ten Kate M, Visser PJ, Bakardjian H, Barkhof F, Sikkes SAM, van der Flier WM, Scheltens P, Hampel H, Habert MO, Dubois B, Tijms BM.

Front Aging Neurosci. 2018 Mar 15;10:67. doi: 10.3389/fnagi.2018.00067. eCollection 2018.

48.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N; Jacqueline Palace on behalf of the MAGNIMS study group.

Nat Rev Neurol. 2018 Mar 20;14(4):213. doi: 10.1038/nrneurol.2018.39.

PMID:
29582852
49.

Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial.

Leijenaar JF, Groeneveld GJ, van der Flier WM, Scheltens P, Klaassen ES, Weinstein HC, Biessels GJ, Barkhof F, Prins ND.

JMIR Res Protoc. 2018 Mar 20;7(3):e80. doi: 10.2196/resprot.9192.

50.

Cerebral Microbleeds: Imaging and Clinical Significance.

Haller S, Vernooij MW, Kuijer JPA, Larsson EM, Jäger HR, Barkhof F.

Radiology. 2018 Apr;287(1):11-28. doi: 10.1148/radiol.2018170803. Review.

PMID:
29558307

Supplemental Content

Loading ...
Support Center